HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Jun-Hsiang Lin Selected Research

PF-06263507

1/2021ASN004, A 5T4-targeting scFv-Fc Antibody-Drug Conjugate with High Drug-to-Antibody Ratio, Induces Complete and Durable Tumor Regressions in Preclinical Models.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Jun-Hsiang Lin Research Topics

Disease

2Neoplasms (Cancer)
01/2021 - 12/2008
1Pruritus (Itching)
01/2020
1Atopic Dermatitis (Atopic Eczema)
01/2020
1Pain (Aches)
06/2003

Drug/Important Bio-Agent (IBA)

1Ado-Trastuzumab EmtansineIBA
01/2021
1AntigensIBA
01/2021
1PF-06263507IBA
01/2021
1Pharmaceutical PreparationsIBA
01/2021
1Glycoproteins (Glycoprotein)IBA
01/2021
1Immunoconjugates (Immunoconjugate)IBA
01/2021
1Sodium Channels (Sodium Channel)IBA
01/2020
1AntipruriticsIBA
01/2020
1Sodium Channel BlockersIBA
01/2020
1Chloroquine (Aralen)FDA LinkGeneric
01/2020
1AntibodiesIBA
12/2008
1CationsIBA
06/2003
1Proteins (Proteins, Gene)FDA Link
06/2003
1Biological ProductsIBA
06/2003

Therapy/Procedure

1Intradermal Injections
01/2020